Less than 10% of patients in the United States enroll in clinical trials, and even lower rates are noted among minority populations. Barriers to recruitment include lack of awareness, strictness of eligibility, and practical concerns, including travel distance and financial costs. The widespread use of social media offers the potential to use dynamic communication mechanisms to reach large, diverse populations-increasing awareness and ultimately accrual to clinical trialsand can be more user friendly than the existing (usually static) online resources. In addition, social media platforms can be used for the dissemination of clinical trial information to participants, ultimately including trial results. However, the use of social media in this setting is not without risks both to interested individuals and to the integrity of the clinical trial. Given the importance of this topic, the National Institutes of Health recently hosted a 2-day workshop entitled 1 When considering the pros and cons of communicating about clinical trials with social media, we should try to place patients at the center to understand the context. If there are issues with clinical trial design or execution, then we need to think about how we develop and operate clinical trials and not blame the patients, who are volunteer participants.
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At the Crossroads of Social Media and Clinical Trials: A Workshop on the Future of Clinician, Patient, and Community
Engagement. 1 When considering the pros and cons of communicating about clinical trials with social media, we should try to place patients at the center to understand the context. If there are issues with clinical trial design or execution, then we need to think about how we develop and operate clinical trials and not blame the patients, who are volunteer participants.
Use of Social Media to Increase Clinical Trial Enrolment
Under enrolment to clinical trials is a significant issue, leading to premature closure, inconclusive results, and a significant waste of financial and other resources. Currently, approximately 12% of trials listed on clinicaltrials.gov are terminated early, more than one-half because of insufficient accrual. 2 Traditional methods of clinical trial recruitment can be passive (such as posting recruitment materials in the clinic so that patients can contact the study team) or active (in which the researchers directly approach the patient). Social media offers a more widespread, rapid, and cost-effective means of recruitment using both passive and active methodology. The vast majority of Americans are online, with four-fifths using the Internet to acquire health-related information. 3 Specifically regarding the recruitment of patients to cancer clinical trials, Sedrak et al noted that social media may provide an infrastructure that allows investigators to interact with the public in new ways, including stimulating interest in new clinical trials with targeted messages to connect patients, caregivers, and families with potential trial enrollment websites. 4 Cooperative groups, in particular the Southwest Oncology Group (SWOG), were early adopters of using social media to increase awareness of their clinical trials. In 2013, they developed a Social Media Working Group with the goal of using social media, specifically Twitter (@SWOG, #SWOGOnc), to promote clinical trial accrual as well as the science of oncology and the value of researchdriven patient care among community and academic oncologists and the lay population. The other National Clinical Trials Network (NCTN) groups have active social media accounts (@ALLIANCE_Org, #AllianceNCTN; @EAOnc, #EAOnc; @GOG; @nrgonc, #nrgoncology; @COGorg) as well as specific meeting hashtags. However, the potential of using social media to enhance clinical trial recruitment has not been fully realized to date, and more work in this area is clearly needed. Sedrak and colleagues noted that, although patients with cancer frequently used the Internet to get information about therapies, less than 20% of the information gathered was related to clinical trials, and there were minimal links back to trial recruitment sites. 4 There are definitive concerns about using social media platforms to recruit patients onto clinical trials. Most of these concerns relate to issues of privacy, confidentiality, and transparency, in which sensitive health information can be made
public. It is clear that many individuals do not understand the risks of using social media platforms, that their information can be sold on to interested third parties, or that the companies may violate their own protocols. Although the onus is on a given individual to understand the risk of sharing information on social media platforms, researchers have an obligation not to amplify these risks and to mitigate them where possible. Therefore, if they choose to use social media for recruitment, then interested individuals should be discouraged from posting their health information on open pages and, rather, should be encouraged to use private channels, such as private messaging, email, or calling. 5 Having "terms of use" for a given website can help with both confidentiality and transparency issues. Terms of use outline the rules of the website for several possible issues, including what types of interactions are expected and tolerated on the site, how personal information shared over the site may be used, and who will have access to that information and for what purposes. 5 Another concern relates to the quality of the posted information, and specifically the need to avoid anything that seems like coercion. Institutional research boards (IRBs) have routinely reviewed paper recruitment materials, but it is less clear how active they are, or indeed can be, in reviewing online materials, making it more difficult to control social misconceptions about the value of clinical trials. Because investigators do not readily know exactly what will be discussed on social media platforms regarding a given clinical trial, prospective discussions with IRBs regarding the planned use of social media to aid trial recruitment is appropriate. 5 Along with this is the issue of how and when conflicts of interest should be divulged on social media platforms. Guidance about how investigators should interact with IRBs regarding the use of social media in clinical trial recruitment is available in a recent document issued by the Harvard Catalyst Regulatory Foundations, Ethics, & Law Program. 6 In this issue of Cancer, Lynch and colleagues, 7 note that prospective evaluation of a clinical trial involving patients upfront can mitigate some of the issues associated with the use of social media in recruitment. One way to combat many potential issues is to post only the publicly available clinical trial information, such as that available on clinicaltrials.gov. However, that site may not be updated, and many patients and advocates monitor cancer conferences for clinical trial updates.
The recruitment of minority populations to clinical trials remains low. Specific barriers to recruiting these populations include awareness, access, and implicit bias.
It is noteworthy that there appears to be a very small difference in willingness to be part of trials between minorities and nonminorities once they are made aware of a given trial. Clearly, social media could be used to increase awareness of trials in these populations, although it would be unlikely to have an impact on other barriers. There are differences in the types of social media platforms used between populations, 5, 8 and knowledge of which platform is most commonly used by a targeted population is important so that it can be effectively reached.
Older patients are the largest, fastest growing segment of the oncology population and are poorly represented in clinical trials. This is a significant issue, because many approved agents will be used in elderly patients after approval, even if the safety of these agents has not been confirmed in older populations. Although their use of social media is considerably less than that in younger populations, it has been steadily increasing. In addition, social media can be used to make family and caregivers aware of clinical trials.
Because 85% of patients with cancer are treated in the community, 9 which may involve rural sites, understanding the use of clinical trial awareness mechanisms, including social media, may be helpful. Virani et al identified rural community outreach barriers, 10 several of which could be overcome by appropriately using social media.
Overall, the appropriate use of social media, with attention to potential risks, is a useful tool for increasing awareness of clinical trials and can improve accrual, including that of minority patients. However, data to "prove" increased accrual by these interventions may be difficult to obtain, but that does not stop other marketing efforts from individual sites, pharma, the National Cancer Institute, and cooperative groups to increase awareness.
Use of Social Media by Participants in Clinical Trials
There are clear benefits from using social media after enrolment with regard to participant support and sharing experiences. However, there are numerous potential drawbacks that can impact clinical trial conduct in several ways. The importance of these potential negatives may not be large and also may not be pragmatically alterable. The scientific integrity of a trial can be impacted as a result of patients "unblinding" themselves or undermining the enrolment of future participants by disseminating inaccurate, anecdotal information. Gelinas et al noted significant issues with the use of social media Cancer December 15, 2018 among study participants, several of which ultimately could impact patient safety. 5 Therefore, although using social media can help support participants in clinical trials, there are several drawbacks, which may not be easy to address.
It is not possible to ask study participants to avoid using social media completely, because this would be a waiver of legal rights and impinges on the First Amendment. However, it may be possible to work with study participants regarding how they interact when using social media platforms. Technical solutions (for example, disabling comments for institutional posts) are a potential solution in some cases. Actively monitoring social media sites is very time-consuming and is not feasible in most instances. However, the easiest, least time-consuming, and cheapest option is better education of patients upfront, especially during the informed-consent process, explaining that the value of their participation in a given trial hinges on the integrity of data collected and the successful completion of the trial and that only if this is accomplished can the trial results produce meaningful advances in patient care. A key question going forward is whether the informed-consent document should contain a paragraph describing appropriate use of social media platforms while an individual is enrolled in a clinical trial.
Lynch and colleagues 7 have developed the Social Media ADEPT approach to address the hazards associated with social media use by study participants. The goal of ADEPT is to: Assess prospectively when and how social media may pose risks for a study, and plan accordingly; Design studies that minimize these risks; Educate participants about the downsides of their social media use and their responsibilities to promote study success; Preempt problems by offering participants other avenues with which to connect and have their questions answered; and, finally, Take additional steps, as needed. A key part of using ADEPT is the involvement of patients and caregivers at all stages to prospectively identify potential issues. This approach confirms the critical importance of educating clinical trial participants in the appropriate use of social media, thereby decreasing the likelihood that the integrity of a trial will be impacted and increasing the likelihood that a trial can be successfully completed.
Use of Social Media to Disseminate Result of Clinical Trials
Social media is used extensively and effectively to disseminate the results of clinical trials. National meetings, such as the American Society of Clinical Oncology annual meeting, were early adopters of using Twitter to rapidly communicate results. Following the American Society of Clinical Oncology, many other organizations (the American Association for Cancer Research, the American Society of Hematology, the European Group for Blood and Marrow Transplantation) have implemented official and less official designated tweeters to allow real-time dissemination of information. This allows amplification of the conference information "signal" to various constituents, including physicians who did not make the meeting, basic science faculty and students who may not attend more clinically oriented meetings, as well as interested patients and the general public. Continued patient engagement in the clinical trial process, including making sure they are aware of the results of trials in which they enrolled, is critical, and the use of social media can be highly effective in achieving this goal. Social media encourages discussion and reminds us that, "Without clinical trials, cancer treatment would always remain the same," 11 and that an educated and engaged (via social media and in real life) public is necessary to sustain a national #clinicaltrials infrastructure.
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Conclusion
In summary, the use of social media is here to stay, and, as investigators, we need to catch up with our patients and use social media appropriately to increase awareness and disseminate information about clinical trials. Clearly, the use of social media can rapidly and effectively accomplish these goals in a cost-effective manner, across large and diverse populations, in a manner that was not previously possible. However, caution is recommended, because the use of social media can have negative consequences, including affecting an individual's privacy and negatively impacting trial conduct, such that successful completion is not possible. It is clear that the onus lies heavily with us as investigators to educate our patients on the appropriate use of social media as it relates to clinical trials. In addition, IRBs will need to consider what role they feasibly may play to protect participants and avoid the dissemination of misinformation in a more complex world in which patients are increasingly engaged and less passive volunteer participants. 6 Approaches like that developed by Lynch et al, which rely heavily on input from potential participants, would appear to be a step in the right direction.
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